SEC Form 4 · accession 0001366268-26-000002
Inhibrx Biosciences, Inc. · INBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Jon Faiz Kayyem
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 4, 2026 · 5:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002007919
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $95.22 | Jun 3, 2026 | A | 15,000 | A | Jun 3, 2027 | Jun 3, 2036 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.